濮阳东方男科收费便宜(濮阳东方妇科价格不贵) (今日更新中)

LOS ANGELES, Sept. 10 (Xinhua) -- Scientists at the University of California Los Angeles campus have announced that they have successfully used new prediction algorithms to forecast climate up to 16 months in advance.Professor Michael Ghil said in a UCLA news release Friday his team used new prediction algorithms based on matching ocean temperature records with new theories on how long-term climate trends are influenced by short-term weather extremes.That's twice as far into the future as previously accomplished.Ghil, a distinguished professor of climate dynamics in the UCLA Department of Atmospheric and Oceanic Sciences and senior author of the research, said the new prediction formulas will give climate experts and governments clues about long-term swings in the El Nino/La Nina oscillation in the Pacific Ocean, which drastically affects weather in the Americas, Asia and Australia.The new forecasting tool uses sea temperatures and has been tested on decades of historical data. The forecasts were then cross-checked against actual climate trends.The UCLA team also said that their 16-month forecasts were more accurate than previous forecasts that went only 8 months forward.Ghil emphasized that the forecasting tools are for climate, which is long-range, global patterns, but not for meteorology, which is short-term weather forecasting."Certain climate features might be predictable, although not in such detail as the temperature and whether it will rain in Los Angeles on such a day two years from now," said Ghil, who is also a member of UCLA's Institute of Geophysics and Planetary Physics. "These are averages over larger areas and longer time spans."The study is currently available online in the journal Proceedings of the National Academy of Sciences (PNAS) and will be published in an upcoming print edition of the journal.

BEIJING, Aug. 5 (Xinhuanet) -- A study conducted by Israeli researchers at the Albert Einstein College of Medicine in New York shows that genes, rather than good eating and lifestyle habits, determine longevity, according to media reports Friday. "This study suggests that centenarians may possess additional longevity genes that help to buffer them against the harmful effects of an unhealthy lifestyle," said senior author Nir Barzilai, director of the Institute for Aging Research at Yeshiva University's Albert Einstein College of Medicine.The study involves 477 Ashkenazi Jews between the ages of 95 and 122, of whom 75 percent are women. According to the study, Ashkenazi Jews are chosen as subjects because they are more "genetically uniform than other populations, making it easier to spot gene differences that are present."The study also found that the long-lived Ashkenazi Jews drank slightly more and exercised less than their average counterparts. But Barzilai also warned: “Although this study demonstrates that centenarians can be obese, smoke and avoid exercise, those lifestyle habits are not good choices for most of us who do not have a family history of longevity.""We should watch our weight, avoid smoking and be sure to exercise, since these activities have been shown to have great health benefits for the general population, including a longer lifespan," He added.

CANBERRA, Aug. 17 (Xinhua) -- Australian scientist on Wednesday said his international research team has discovered the trick on how butterfly learn to change its wing pattern to avoid being eaten by birds.The Amazonian butterfly, Heliconius numata, has learnt to carry out a single genetic switch to alter its wing pattern so it appears to be another bad-tasting butterfly that birds will avoid.Dr. Siu Fai (Ronald) Lee from the Department of Genetics and Bio21 Institute at Australia's University of Melbourne was part of the international research team, which was led by scientists at Centre National de la Recherche Scientifique (CNRS) and the University of Exeter in United Kingdom.Dr. Lee said the historical mystery had puzzled researchers for decades."Charles Darwin was puzzled by how butterflies evolved such similar patterns of warning coloration," Dr. Siu Fai (Ronald) Lee from the Department of Genetics and Bio21 Institute at the University of Melbourne told Western Australia Today."We have now solved this mystery, identifying the region of chromosome responsible for changing wing pattern."He said the research team identified a genetic switch known as a supergene, which allowed the butterfly to morph into several different forms, allowing one species to mimic another."It is amazing that by changing just one small region of the chromosomes, the butterfly is able to fool its predators by mimicking a range of different butterflies that taste bad," he said."The butterflies rearrange this supergene DNA like a small pack of cards, and the result is new wing patterns. It means that butterflies look completely different but have the same DNA."There are other butterflies doing similar tricks, but this is the most elegant one."I was just fascinated by how elegant they were."He said the discovery proves that small chromosomal changes can preserve successful gene combinations, and thus help a species to adapt.The findings of the study are published on August 14 in the international journal Nature.

BEIJING, Aug. 23 (Xinhuanet) -- More than 90 percent of U.S. heart attack patients who need the lifesaving procedure receive it within just 90 minutes of being admitted to the hospital, according to a study released Monday in the journal Circulation.The study on the American Heart Association's journal shows that in 2010, 91 percent of heart attack patients who needed angioplasty were treated within the 90-minute window. While in 2005, 44% were.Researchers analyzed data on more than 300,000 such patients who underwent emergency angioplasty between January of 2005 and October of 2010.The improvement is the result of a nationwide effort between federal agencies, health care organizations and health care providers to improve heart attack care and outcome, said study author Dr. Harlan M. Krumholz, a professor of medicine and epidemiology and public health at Yale University School of Medicine, according to U.S. News reports.

WELLINGTON, June 7 (Xinhua) -- Scientists in New Zealand have developed a new drug to fight previously untreatable hypoxic cancer tumors, which form in areas of the body starved of oxygen.The researchers at the Auckland University have entered an agreement for the clinical development of CEN-209, which was developed over 10 years of research, said a statement from the university Tuesday.CEN-209 was designed to enhance the effectiveness of radiotherapy and chemotherapy in solid hypoxic tumors, which were resistant to standard cancer therapies, said the statement. In lung cancer patients for example, about half of tumors had hypoxic regions.The new drug worked by damaging the DNA of hypoxic cancer cells, while leaving normal, healthy tissues alone.CEN-209 was designed and created by researchers at the university's Auckland Cancer Society Research Centre (ACSRC), using computer models of drug transport within tumors to accurately predict the anti-tumor activity of the drugs."Our computer models of drug transport developed in-house allowed the synthetic chemists to test their design theories and considerably shortened the discovery process," said Associate Professor Michael Hay, who led the ACSRC research chemists."CEN-209 improves markedly on previous agents in this class in terms of its ability to penetrate tumors, and this is reflected by its improved activity in the laboratory, when combined with long or short courses of radiotherapy," said researcher Professor Bill Wilson.Under the agreement between the university's Auckland UniServices Ltd. and California-based Centella Therapeutics, Inc., a subsidiary of Varian Medical Systems, Inc., Centella will have exclusive rights to CEN-209, which it will develop and trial with Cancer Research UK.The work on CEN-209 is the culmination of a program initiated with funding from the U.S. National Cancer Institute, and more recently from the Maurice Wilkins Centre for Biodiscovery. Ongoing preclinical research on CEN-209 and a backup compound was funded by grants from the Auckland Medical Research Foundation, Genesis Oncology Trust and Health Research Council of New Zealand, said the statement.

来源：资阳报